Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
ACQUIRED COMPANY
 
My Lists

Affymax  (Stock symbol: AFFY ) Acquired by Glaxo Welcome (1995 $ 529,000,000)

4001 Miranda Avenue
Palo Alto, CA 94304
USA
(650)-812-8700
Website Company Summary Management Team
Board

Outside board: (May no longer be on the board) Kathleen LaPorte (New Leaf Venture Partners) John A. Orwin (Affymax Former CEO) Hollings C. Renton (Onyx Pharmaceuticals Former CEO) Daniel K. Spiegelman (CV Therapeutics CFO) Ted W. Love (Nuvelo President/CEO) John P. Walker (Novacea Interim CEO) Christian van Heek (BIO POINT Group Managing Director) Keith R. Leonard (Kythera Biopharmaceuticals President/CEO)
Former outside board: J. Leighton Read (Alloy Ventures General Partner) Hironori Hozoji (JAFCO Life Science Investment) Elizabeth Czerepak (Bear Stearns Health Innoventures) Carl Djerassi (Stanford Medical Center);  R. Lee Douglas (COR Therapeutics co-Founder) Nicholas Galakatos (MPM Capital) Robert Glaser (Markey Charity Trust);  Steven D. Goldby (MDL Information Systems CEO) R. Scott Greer (Abgenix) Baron Kraijenhoff (Akzo Nobel V Chem);  Lori F. Rafield (Apax Partners) Lewis Sarett (Merck Sr. VP);  Alejandro Zaffaroni (UCSF Medical Center)
Company

Business description: The new Affymax is building upon its proven discovery platform and extensive pharmaceutical experience to build a pipeline of peptide drugs to treat cancer and immune-mediated diseases. The powerful combination of broad management experience, clinical development know-how, a proven drug discovery engine and strong intellectual property, positions Affymax as a preeminent drug discovery and development company. The Company has been a pioneer in chemistry and high throughput screening technologies that enable faster and more efficient processes for drug discovery by integrating proprietary chemistries, innovative molecular biology techniques, sophisticated software and instrumentation technology.
Partners include: ALZA PharmaceuticalsDow ChemicalMolecular Dynamics;  Amer Home Products;  Ciba Geigy;  Genetic Institute;  Takeda Pharmaceutical
Capital

Rounds: 5
Recent Fundings: Apr 2006   Jul 2005
Capital raised: 160.0M
Last Round: 10.0M
Ownership: Acquired by Glaxo Welcome (1995 $ 529,000,000)
Stock Symbol: AFFY
Corporate investors: Intuit;  Ciba Geigy;  Dow Chemical;  Marion Merrill Dow;  InterHealth;  Maxwell Communications

Last Tweets


 

Last Mentions


Overview
Record updated: May 2013
Sector: Biotech
Headcount: 101-150 as of Mar 2014
Rounds: 5
Recent Fundings: Apr 2006   Jul 2005
Capital Raised: 160.0M
Last Round: 10.0M
Ownership: Acquired by Glaxo Welcome (1995 $ 529,000,000)
Stock Symbol: AFFY